Peptide therapy for longevity targets the biological mechanisms of aging — mitochondrial function, cellular repair, and growth hormone axis regulation. Getting started requires the right sequencing: labs first, then compound selection, then careful cycling. Here is the step-by-step guide.
Peptide therapy has moved from research literature into clinical practice as an approach to healthspan — the years of life spent in good functional health. Unlike generic anti-aging supplements, compounded peptides act on specific biological pathways with measurable biomarker endpoints. This guide covers the nine-step process a thorough provider evaluation would walk through, from baseline assessment through protocol cycling. Note: all peptides referenced here are compounded and not FDA-approved. Protocols are subject to provider evaluation and approval is not guaranteed.
Step 1: Understand What Longevity Peptides Actually Target
Longevity peptides do not stop aging. What they aim to do is modulate specific biological processes that accelerate age-related decline. The foundational science — articulated in a landmark 2013 Cell paper by López-Otín and colleagues — describes aging through nine hallmarks: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
Different longevity peptides map to different hallmarks:
- CJC-1295 + Ipamorelin: deregulated nutrient sensing (GH/IGF-1 axis), body composition, sleep architecture
- Epitalon: telomere attrition, epigenetic regulation, pineal function
- MOTS-c: mitochondrial dysfunction, metabolic efficiency
- BPC-157: loss of proteostasis, tissue repair signaling
- GHK-Cu: genomic instability, skin and connective tissue repair
Understanding what you are targeting is the foundation of a coherent protocol. Beginning multiple compounds without defined goals produces poor outcomes and complicates monitoring.
Step 2: Build the Biological Foundation First
Peptide therapy is not a substitute for foundational health practices. Research consistently shows that poor sleep, chronic metabolic dysfunction, nutritional deficiencies, and sedentary behavior create biological conditions that override or mask the effects of any compound.
Before starting a peptide protocol, ensure:
- Sleep is optimized (7–9 hours; sleep-disordered breathing is addressed if present)
- Metabolic markers are not severely deranged (uncontrolled diabetes, active thyroid disease, or severe obesity will complicate both protocol design and interpretation)
- Nutritional adequacy for protein, micronutrients (vitamin D, magnesium, zinc), and caloric status
- Resistance training is part of weekly practice — GH axis peptides in particular produce significantly better body composition outcomes when combined with progressive resistance training
Step 3: Get Baseline Labs Before You Start
A responsible protocol starts with objective data. Baseline labs allow providers to:
- Confirm GH/IGF-1 status before adding GH-stimulating peptides (to avoid pushing already-elevated IGF-1 further)
- Rule out contraindications (active malignancy, pituitary pathology, hormone-sensitive conditions)
- Set a reference point for tracking response over 3–6 months
Typical baseline labs for a longevity peptide evaluation include: IGF-1, comprehensive metabolic panel, CBC, thyroid panel (TSH, free T3, free T4), sex hormones (testosterone, estradiol, SHBG), cortisol, and inflammatory markers (hs-CRP, homocysteine). Additional testing may be added based on specific compounds of interest.
Step 4: Choose Compounds Based on Your Goals
| Peptide | Primary Target | Typical Cycle | Evidence Level |
|---|---|---|---|
| CJC-1295 + Ipamorelin | GH axis, body composition, sleep, recovery | 3 months on, 1 month off | Moderate (human pharmacology data) |
| Epitalon | Telomere length, melatonin regulation, epigenetic aging | 10–20 day course, 1–2× per year | Early human trials (Russian research base) |
| MOTS-c | Mitochondrial biogenesis, metabolic flexibility, insulin sensitivity | 4–6 weeks on, cycling | Emerging (animal + early human data) |
| BPC-157 | Tissue repair, gut integrity, tendon/ligament healing | 4–12 weeks depending on indication | Animal models; limited human trials |
| GHK-Cu | Collagen synthesis, wound healing, skin biology | Varies; often topical or injectable cycles | In vitro + early clinical data |
Compound selection is not a consumer decision — it requires a licensed provider to review your labs, health history, and goals. This table is educational context, not a prescription recommendation.
Step 5: Start with Growth Hormone Axis Support
For most patients beginning longevity peptide therapy, the GH axis is the logical entry point. GH declines at approximately 14–15% per decade after age 30. The downstream effects — reduced lean mass, increased adiposity, degraded sleep architecture, slower recovery — are among the most functionally significant aspects of age-related biological change.
CJC-1295 (a GHRH analog) combined with ipamorelin (a selective GHSR-1a agonist) is the most commonly prescribed GH axis protocol in compounded peptide practice. The combination acts on complementary pathways to produce a synergistic, pulsatile GH pulse without the cortisol or appetite side effects of earlier secretagogues.
Review the CJC-1295 + ipamorelin research stack before your evaluation to understand what the evidence supports.
Step 6: Add Cellular and Epigenetic Compounds
After establishing GH axis support, a second tier of compounds targeting cellular aging mechanisms may be considered by your provider.
Epitalon is a synthetic tetrapeptide derived from the pineal peptide extract epithalamin. It has been studied for effects on telomerase activation, melatonin regulation, and epigenetic markers of aging. The human clinical data originates primarily from Russian gerontology research; the compound has not been studied in large-scale Western randomized controlled trials. A provider evaluation would weigh this evidence quality in the context of your goals. Read the Epitalon research guide.
MOTS-c is a mitochondria-derived peptide encoded in the mitochondrial genome. Research published in Nature Communications by Reynolds and colleagues (2021) demonstrated that MOTS-c levels decline with age and that exogenous MOTS-c administration in aged mouse models improved physical performance, metabolic markers, and insulin sensitivity. Early human data is limited but emerging. Read the MOTS-c research overview.
Step 7: Support Tissue Integrity with BPC-157
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a gastric protein sequence. It has been studied extensively in animal models for its effects on tissue repair — including tendon and ligament healing, gut mucosal integrity, and inflammatory modulation.
In a longevity protocol, BPC-157 is most commonly included when there is an active tissue healing need (joint issues, soft tissue injury, gut integrity concerns) rather than as a universal longevity compound. Human clinical trial data remains limited; most evidence is from rodent models. A 2026 review in Frontiers in Aging (PMC13095733) provided a current summary of the therapeutic peptide landscape including BPC-157 tissue repair mechanisms. Review the BPC-157 patient guide.
Step 8: Monitor Progress with Follow-Up Labs
At 3–6 months into a protocol, follow-up labs allow objective assessment of response. Key markers to recheck include:
- IGF-1: Should rise from baseline if GH axis peptides are working; should remain within normal physiologic range (excessive IGF-1 elevation is a signal to adjust protocol)
- Body composition: DEXA scan or validated impedance measurement to track lean mass and fat mass changes
- Metabolic panel: Fasting glucose, insulin, HbA1c — GH axis activation can transiently affect insulin sensitivity
- Inflammatory markers: hs-CRP, if baseline was elevated, to assess anti-inflammatory progress
- Telomere length: If Epitalon was used, some providers track this via commercial testing as an exploratory marker
Monitoring is not optional — it is the mechanism by which your provider adjusts the protocol based on actual biological response rather than subjective impression alone.
Step 9: Cycle Off and Reassess
Peptide protocols are not intended for indefinite continuous use. Cycling serves multiple purposes: preventing receptor downregulation, allowing assessment of baseline status post-treatment, and reducing long-term compound burden. A standard approach cycles most GH axis peptides 3 months on / 1 month off, with longer-acting epigenetic compounds (Epitalon) used in shorter, infrequent courses.
At each reassessment, your provider evaluates labs, symptom response, and goals to determine whether to continue, modify, or discontinue the protocol. This iterative evaluation process is the foundation of responsible peptide therapy. Ready to begin? Start your private evaluation at TelosRX — an asynchronous telehealth provider that allows you to complete your evaluation on your own schedule.
Frequently Asked Questions
How long before longevity peptide therapy produces measurable effects?
Timeline depends on the compound and endpoint. IGF-1 changes from GH axis peptides are typically measurable at 4–8 weeks. Subjective improvements in sleep and energy are often reported in the first month. Body composition changes develop over 3–6 months. Epigenetic markers like telomere length are slower to change and harder to attribute causally to any single intervention.
Can longevity peptides be used alongside HRT (hormone replacement therapy)?
Many patients use GH axis peptides concurrently with testosterone or estrogen replacement. The interactions are generally additive rather than antagonistic. However, combining multiple hormonal and peptide therapies increases the complexity of monitoring and the importance of experienced provider oversight.
Are longevity peptides legal?
Compounded peptides are prepared under federal compounding regulations. They are not FDA-approved as finished pharmaceutical products. The regulatory landscape evolves; a current provider evaluation will account for what compounds are currently available for compounding.
Do I need to inject longevity peptides?
Most longevity peptides are administered via subcutaneous injection because oral bioavailability is very low — peptides are degraded by stomach acid and digestive enzymes before absorption. Some compounds (like GHK-Cu) can be used topically. Your provider determines the administration route appropriate for your protocol.
What distinguishes a responsible longevity peptide provider?
A responsible provider orders baseline labs before prescribing, selects compounds based on your individual biomarker profile and goals, provides a monitoring schedule, and adjusts the protocol based on lab response. Protocols prescribed without labs or with no monitoring plan are a flag for substandard practice.
How much does peptide therapy for longevity cost?
Costs vary significantly based on compounds selected, protocol duration, and monitoring intensity. Compounded peptides are not covered by insurance. A provider evaluation is the starting point to understand what a personalized protocol would involve and cost for your specific situation.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.